Uğur Şahin, BioNTech CEO (Kay Nietfeld/picture-alliance/dpa/AP Images)
February 4, 2022 01:46 PM EST
FDA+

BioN­Tech wait­ed to col­lect its $100M PRV un­til just be­fore Mod­er­na's Covid-19 vac­cine ap­proval

Zachary Brennan

Senior Editor

The FDA on Fri­day re­leased a new let­ter sent last week to BioN­Tech and Pfiz­er re­gard­ing their qui­et­ly held pri­or­i­ty re­view vouch­er. De­spite the fact …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times